Kyowa Hakko Kirin signs second big pharma deal for mogamulizumab
This article was originally published in Scrip
Executive Summary
Pfizer is the second big pharma firm to team up with Kyowa Hakko Kirin to develop the latter firm's anti-CCR4 antibody mogamulizumab in a combination cancer treatment.